Get the Stockscreener App
472.55
1.71%
-8.615
Vertex Pharmaceuticals Inc stock is traded at $472.55, with a volume of 416.68K.
It is down -1.71% in the last 24 hours and up +15.82% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$481.16
Open:
$478.98
24h Volume:
416.68K
Relative Volume:
0.27
Market Cap:
$123.91B
Revenue:
$10.63B
Net Income/Loss:
$-479.80M
P/E Ratio:
-237.46
EPS:
-1.99
Net Cash Flow:
$-1.35B
1W Performance:
+2.43%
1M Performance:
+15.82%
6M Performance:
+1.51%
1Y Performance:
+12.85%
1-Day Range:
$472.39
$480.47
1-Week Range:
$458.74
$491.81
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
472.98 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.98 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.70 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.19 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.83 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $501 From $500 -February 07, 2025 at 09:40 am EST - Marketscreener.com
Telos Capital Management Inc. Acquires 1,605 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Retirement Systems of Alabama Sells 166,947 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Cullinan Associates Inc. Reduces Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Greenwood Capital Associates LLC Has $7.44 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by abrdn plc - MarketBeat
E. Ohman J or Asset Management AB Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex challenger Sionna prices $191M IPO - BioPharma Dive
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Jennison Associates LLC - MarketBeat
U.S. Capital Wealth Advisors LLC Has $917,000 Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Alliance Wealth Advisors LLC UT Makes New $377,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
UnitedHealth, Vertex Pharmaceuticals, Axon Enterprise And A Major Energy Stock: CNBC's 'Final Trades' - Benzinga
ICER evidence report on Vertex new treatment for acute pain - The Pharma Letter
Yousif Capital Management LLC Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Concord Wealth Partners Boosts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
DAVENPORT & Co LLC Has $87.64 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara - Barchart
Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise - CNBC
Kingswood Wealth Advisors LLC Sells 3,773 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings? - Yahoo Finance
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Lockheed Martin Investment Management Co. Sells 1,660 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Hager Investment Management Services LLC Purchases Shares of 5,384 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Cassia Capital Partners LLC Decreases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Concord Asset Management LLC VA Purchases 741 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
After Vertex's FDA pain drug win, Algiax pushes ahead with new non-opioid challenger - FirstWord Pharma
Vertex Pharmaceuticals (NASDAQ:VRTX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug - MSN
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller - MSN
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now? - The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges - MSN
Vertex Pharmaceuticals' (VRTX) "Outperform" Rating Reiterated at William Blair - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to "Equal Weight" Rating by Wells Fargo & Company - MarketBeat
Hantz Financial Services Inc. Has $507,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury
Country Trust Bank Lowers Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance Australia
Vertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
VRTX: 3 Genomic Stocks at the Forefront of Precision Medicine - StockNews.com
Vertex Pharmaceuticals Unusual Options Activity - Benzinga
The first shot taken at Medicaid, and Optum’s wellness visit ad - STAT
3 Magnificent Stocks to Buy and Hold Forever - The Motley Fool
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains? - Yahoo Finance
Vertex stock price target raised to $550 at H.C. Wainwright - MSN
FDA Approval of Journavx: High Pricing Challenges Market Penetration, Neutral Impact on Vertex Stock - TipRanks
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):